There is no such thing as a silly question when it comes to biotech and this is actually far from a silly question. Yes I think there certainly is a place for Bisantrene as a primary treatment, the problem is the FDA won’t let you run a trial where you test in the front line as they consider it unethical to risk a patient’s life by denying them an treatment that is known to be effective. You need to trial it as a second or third line treatment for R/R AML. Once approved you could run a new primary treatment trial, but not before you get approval for a later point in the treatment pathway.
If the MRD approach works out it won’t really matter anyway. Bisantrene would be licensed for treating MRD(+) patients (about 25%) and it would almost certainly be used off-label for the MRD(-) patients since they still have a reasonable chance of relapsing too. It would likely end up being used in as many patients as if it was a primary treatment.
Not considering off-label use is one area where @wombat777’s analysis of future revenue may be too conservative. It makes a big difference to the financial projections if you include off-label use - it will basically increase the potential revenue 4x on the MRD path.
- Forums
- ASX - By Stock
- RAC
- 1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML)
1993: 5 of a total of 7 (72%) patients achieved total eradication of their cancer (R/R AML), page-25
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.50 |
Change
0.000(0.00%) |
Mkt cap ! $255.5M |
Open | High | Low | Value | Volume |
$1.50 | $1.50 | $1.50 | $22.88K | 15.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $1.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 1.480 |
1 | 16949 | 1.475 |
1 | 950 | 1.470 |
5 | 8434 | 1.465 |
2 | 935 | 1.460 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 1500 | 1 |
1.500 | 1834 | 2 |
1.515 | 5728 | 1 |
1.520 | 650 | 1 |
1.530 | 2355 | 1 |
Last trade - 10.07am 22/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |